	US 12,029,711 B1
	Dosage forms of mirdametinib
Piero L. Ruggiero, Stamford, CT (US); Kristin Patterson, Stamford, CT (US); Mark Hatcher, Stamford, CT (US); Jiping Liu, Stamford, CT (US); Uchenna H. Iloeje, Stamford, CT (US); and Abraham J. Langseth, Stamford, CT (US)
Assigned to SPRINGWORKS THERAPEUTICS, INC., Stamford, CT (US)
Filed by SpringWorks Therapeutics, Inc., Stamford, CT (US)
Filed on Mar. 18, 2024, as Appl. No. 18/608,735.
Application 18/608,735 is a continuation of application No. PCT/US2024/020241, filed on Mar. 15, 2024.
Claims priority of provisional application 63/490,626, filed on Mar. 16, 2023.
Int. Cl. A61K 31/166 (2006.01); A61K 9/00 (2006.01); A61K 9/48 (2006.01)

CPC A61K 31/166 (2013.01) [A61K 9/0053 (2013.01); A61K 9/4825 (2013.01); A61K 9/4833 (2013.01); A61K 9/4858 (2013.01); A61K 9/4866 (2013.01)]

30 Claims

1. An oral dosage form comprising (a) mirdametinib having a d90 no more than 250 microns and (b) one or more pharmaceutically acceptable excipients.